Verona Income Before Tax vs Ebit Analysis
| VRNA Stock | USD 38.81 0.95 2.51% |
Verona Pharma financial indicator trend analysis is much more than just breaking down Verona Pharma PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verona Pharma PLC is a good investment. Please check the relationship between Verona Pharma Income Before Tax and its Ebit accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Income Before Tax vs Ebit
Income Before Tax vs Ebit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verona Pharma PLC Income Before Tax account and Ebit. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Verona Pharma's Income Before Tax and Ebit is 0.98. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Ebit in the same time period over historical financial statements of Verona Pharma PLC, assuming nothing else is changed. The correlation between historical values of Verona Pharma's Income Before Tax and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Verona Pharma PLC are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Income Before Tax i.e., Verona Pharma's Income Before Tax and Ebit go up and down completely randomly.
Correlation Coefficient | 0.98 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Verona Pharma income statement and is an important metric when analyzing Verona Pharma PLC profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Ebit
Most indicators from Verona Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Verona Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 582.8 K, whereas Sales General And Administrative To Revenue is forecasted to decline to 17.17.
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 79.4M | 49.3M | 17.3M | 19.8M | Depreciation And Amortization | 629K | 636K | 679.6K | 713.6K |
Verona Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Verona Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verona Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 59.2M | 204.2M | 186.6M | 259.5M | 308.1M | 323.5M | |
| Total Current Liabilities | 12.6M | 14.2M | 33.4M | 19.0M | 8.7M | 7.7M | |
| Total Stockholder Equity | 44.4M | 184.9M | 148.0M | 230.5M | 249.3M | 261.7M | |
| Net Debt | (28.8M) | (182.0M) | (142.6M) | (217.2M) | (220.4M) | (209.4M) | |
| Retained Earnings | (131.9M) | (207.1M) | (263.7M) | (333.1M) | (388.4M) | (369.0M) | |
| Accounts Payable | 1.9M | 178K | 10.0M | 2.9M | 3.5M | 3.7M | |
| Cash | 30.1M | 188.0M | 148.4M | 227.8M | 271.8M | 285.4M | |
| Non Current Assets Total | 5.5M | 1.7M | 16.5M | 16.5M | 18.4M | 19.3M | |
| Cash And Short Term Investments | 40.3M | 188.0M | 148.4M | 227.8M | 271.8M | 285.4M | |
| Net Receivables | 9.8M | 8.3M | 15.6M | 9.3M | 11.0M | 11.5M | |
| Common Stock Shares Outstanding | 13.2M | 32.9M | 59.1M | 66.1M | 79.3M | 75.3M | |
| Liabilities And Stockholders Equity | 59.2M | 204.2M | 186.6M | 259.5M | 308.1M | 323.5M | |
| Inventory | 3.5M | 4.5M | 4.0M | 2.5M | 1.0 | 0.95 | |
| Other Current Assets | 10.2K | 6.3M | 6.1M | 5.9M | 7.0M | 7.3M | |
| Other Stockholder Equity | 158.0M | 364.7M | 384.5M | 527.6M | 599.5M | 629.5M | |
| Total Liab | 14.8M | 19.4M | 38.6M | 29.0M | 58.8M | 61.8M | |
| Total Current Assets | 53.7M | 202.5M | 170.1M | 243.0M | 289.7M | 304.2M | |
| Common Stock | 6.9M | 31.8M | 31.9M | 40.5M | 42.8M | 44.9M | |
| Other Current Liab | 10.1M | 12.4M | 22.6M | 15.2M | 4.0M | 5.9M | |
| Property Plant And Equipment Net | 1.3M | 1.2M | 979K | 927K | 2.9M | 3.0M | |
| Good Will | 596.0K | 559.6K | 578.2K | 545K | 490.5K | 466.0K | |
| Short Term Investments | 66.0M | 57.0M | 10.3M | 10.3M | 11.8M | 20.1M | |
| Property Plant And Equipment Gross | 43K | 1.2M | 979K | 927K | 2.9M | 3.0M | |
| Net Tangible Assets | 42.2M | 184.3M | 167.7M | 229.9M | 264.4M | 277.6M | |
| Property Plant Equipment | 1.4M | 1.2M | 979K | 927K | 1.1M | 1.1M | |
| Short Term Debt | 603.1K | 1.6M | 648K | 675K | 1.2M | 694.2K | |
| Non Current Liabilities Total | 2.2M | 5.1M | 5.2M | 10.0M | 50.1M | 52.7M | |
| Capital Lease Obligations | 951K | 1.3M | 934K | 880K | 3.0M | 3.1M | |
| Short Long Term Debt Total | 1.2M | 5.9M | 5.8M | 10.6M | 51.3M | 53.9M | |
| Current Deferred Revenue | 0.0 | 10.9M | 22.4M | 1.0 | 1.15 | 1.09 | |
| Net Invested Capital | 44.4M | 189.5M | 152.9M | 240.2M | 297.7M | 174.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.